Biotech Values

[mcbio]

ASMB @ Jefferies HBV summit (3/18/19)

I just listened to the ASMB presentation at this conference and the CEO stated that they will soon have a 4th and possibly even 5th CpAM drug in development for HBV. With P2 data due for their lead CpAM next quarter, I can't say this exactly inspires a lot of confidence. What is wrong with the first 3 CpAMs for HBV? I can honestly say I've never seen a lead drug already being developed over so many times so early in its development.